Canadian Investment Banking Group: Maintaining the Pulmonx (LUNG.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $16.00 to $15.00.
Pulmonx Analyst Ratings
Canaccord Genuity Maintains Buy on Pulmonx, Lowers Price Target to $15
Navigating 6 Analyst Ratings For Pulmonx
Pulmonx Analyst Ratings
Piper Sandler Remains a Buy on Pulmonx (LUNG)
Analyst Ratings For Pulmonx
Pulmonx Analyst Ratings
Wells Fargo Adjusts Pulmonx's Price Target to $16 From $15, Keeps Overweight Rating
Buy Rating for Pulmonx: Strategic Growth and Global Expansion Underpin Optimism
Canaccord Genuity Maintains Buy on Pulmonx, Lowers Price Target to $12
Pulmonx Analyst Ratings
Pulmonx (LUNG) Receives a Buy From Craig-Hallum
Piper Sandler Sticks to Their Buy Rating for Pulmonx (LUNG)
Analysts Conflicted on These Healthcare Names: Revvity (RVTY), Pulmonx (LUNG) and Roche Holding AG (OtherRHHVF)
Analysts Are Bullish on Top Healthcare Stocks: Pulmonx (LUNG), Ligand Pharma (LGND)
Analysts Offer Insights on Healthcare Companies: Reneo Pharmaceuticals (RPHM), Pulmonx (LUNG) and Orchestra BioMed Holdings (OBIO)
Analysts Offer Insights on Healthcare Companies: Pulmonx (LUNG), Arcus Biosciences (RCUS) and 89bio (ETNB)
Craig-Hallum Initiates Coverage On Pulmonx With Buy Rating, Announces Price Target of $18
Pulmonx Analyst Ratings
No Data